{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:08:37Z","timestamp":1783908517395,"version":"3.55.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Natural Science Foundation of Chongqing, China; MSC-exosome was used to study the interaction between TGF-\u03b2 and Wnt signaling pathway in chronic allograft nephropathy","award":["CSTB2022NSCQMSX0079"],"award-info":[{"award-number":["CSTB2022NSCQMSX0079"]}]},{"name":"The doctoral program of the first affiliated hospital of Chongqing Medical University","award":["CYYY-BSYJSCXXM-202332"],"award-info":[{"award-number":["CYYY-BSYJSCXXM-202332"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00210-026-05233-9","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T04:40:58Z","timestamp":1774845658000},"page":"13661-13676","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database"],"prefix":"10.1007","volume":"399","author":[{"given":"Lifeng","family":"Dan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zecang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueli","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangtao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhikang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"5233_CR1","doi-asserted-by":"publisher","DOI":"10.1530\/erc-22-0301","author":"SM Abuzakhm","year":"2023","unstructured":"Abuzakhm SM, Sukrithan V, Fruth B, Qin R, Strosberg J, Hobday TJ, Semrad T, Reidy-Lagunes D, Kindler HL, Kim GP, Knox JJ, Kaubisch A, Villalona-Calero M, Chen H, Erlichman C, Shah MH (2023) A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors. Endocr Relat Cancer. https:\/\/doi.org\/10.1530\/erc-22-0301","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"5233_CR2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ygyno.2018.05.018","volume":"150","author":"C Aghajanian","year":"2018","unstructured":"Aghajanian C, Filiaci V, Dizon DS, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender DP, O\u2019Malley DM, Stuckey A, Gao J, Dao F, Soslow RA, Lankes HA, Moore K, Levine DA (2018) A phase II study of frontline paclitaxel\/carboplatin\/bevacizumab, paclitaxel\/carboplatin\/temsirolimus, or ixabepilone\/carboplatin\/bevacizumab in advanced\/recurrent endometrial cancer. Gynecol Oncol 150(2):274\u2013281. https:\/\/doi.org\/10.1016\/j.ygyno.2018.05.018","journal-title":"Gynecol Oncol"},{"key":"5233_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060857","author":"D Basile","year":"2019","unstructured":"Basile D, Di Nardo P, Corvaja C, Garattini SK, Pelizzari G, Lisanti C, Bortot L, Da Ros L, Bartoletti M, Borghi M, Gerratana L, Lombardi D, Puglisi F (2019) Mucosal injury during anti-cancer treatment: from pathobiology to bedside. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11060857","journal-title":"Cancers (Basel)"},{"issue":"4","key":"5233_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM (1998) A bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54(4):315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466","journal-title":"Eur J Clin Pharmacol"},{"key":"5233_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.848673","volume":"13","author":"L Belkacemi","year":"2022","unstructured":"Belkacemi L, Sun Y, Darmani NA (2022) Evidence for bell-shaped dose-response emetic effects of temsirolimus and analogs: the broad-spectrum antiemetic efficacy of a large dose of temsirolimus against diverse emetogens in the least shrew (Cryptotis parva). Front Pharmacol 13:848673. https:\/\/doi.org\/10.3389\/fphar.2022.848673","journal-title":"Front Pharmacol"},{"issue":"1","key":"5233_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1586\/14737140.2014.864562","volume":"14","author":"L Bergmann","year":"2014","unstructured":"Bergmann L, Maute L, Guschmann M (2014) Temsirolimus for advanced renal cell carcinoma. Expert Rev Anticancer Ther 14(1):9\u201321. https:\/\/doi.org\/10.1586\/14737140.2014.864562","journal-title":"Expert Rev Anticancer Ther"},{"key":"5233_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00922-5","author":"MA Bilen","year":"2025","unstructured":"Bilen MA, Vo BT, Liu Y, Greenwald R, Davarpanah AH, McGuire D, Shiradkar R, Li L, Midya A, Nazha B, Brown JT, Williams S, Session W, Russler G, Caulfield S, Joshi SS, Narayan VM, Filson CP, Ogan K, Kucuk O, Carthon BC, Del Balzo L, Cohen A, Boyanton A, Prokhnevska N, Cardenas MA, Sobierajska E, Jansen CS, Patil DH, Nicaise E, Osunkoya AO, Kissick HT, Master VA (2025) Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial. Nat Cancer. https:\/\/doi.org\/10.1038\/s43018-025-00922-5","journal-title":"Nat Cancer"},{"issue":"1","key":"5233_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1634\/theoncologist.2011-0111","volume":"17","author":"CB Boers-Doets","year":"2012","unstructured":"Boers-Doets CB, Epstein JB, Raber-Durlacher JE, Ouwerkerk J, Logan RM, Brakenhoff JA, Lacouture ME, Gelderblom H (2012) Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 17(1):135\u2013144. https:\/\/doi.org\/10.1634\/theoncologist.2011-0111","journal-title":"Oncologist"},{"issue":"Suppl 2","key":"5233_CR9","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/CCO.0b013e32835de8ee","volume":"25","author":"K Bouabdallah","year":"2013","unstructured":"Bouabdallah K, Ribrag V, Terriou L, Soria JC, Delarue R (2013) Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects. Curr Opin Oncol 25(Suppl 2):S1-12. https:\/\/doi.org\/10.1097\/CCO.0b013e32835de8ee","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"5233_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"5233_CR11","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1007\/s10637-011-9742-1","volume":"30","author":"AH Bryce","year":"2012","unstructured":"Bryce AH, Rao R, Sarkaria J, Reid JM, Qi Y, Qin R, James CD, Jenkins RB, Boni J, Erlichman C, Haluska P (2012) Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors. Invest New Drugs 30(5):1934\u20131941. https:\/\/doi.org\/10.1007\/s10637-011-9742-1","journal-title":"Invest New Drugs"},{"issue":"1\u20136","key":"5233_CR12","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3233\/cbm-2011-0176","volume":"9","author":"P Cairns","year":"2010","unstructured":"Cairns P (2010) Renal cell carcinoma. Cancer Biomark 9(1\u20136):461\u2013473. https:\/\/doi.org\/10.3233\/cbm-2011-0176","journal-title":"Cancer Biomark"},{"key":"5233_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1517546","volume":"15","author":"J Cao","year":"2024","unstructured":"Cao J, Chen Z, Wang Y, Ma Y, Yang Z, Cai J, Xiao Z, Xu F (2024) Overweight and glucose\/lipid metabolism abnormality associated with SSRIs: a pharmacovigilance study based on the FDA adverse event reporting system. Front Pharmacol 15:1517546. https:\/\/doi.org\/10.3389\/fphar.2024.1517546","journal-title":"Front Pharmacol"},{"issue":"4","key":"5233_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.adaj.2017.10.024","volume":"149","author":"MS Chambers","year":"2018","unstructured":"Chambers MS, Rugo HS, Litton JK, Meiller TF (2018) Stomatitis associated with mammalian target of rapamycin inhibition: a review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer. J Am Dent Assoc 149(4):291\u2013298. https:\/\/doi.org\/10.1016\/j.adaj.2017.10.024","journal-title":"J Am Dent Assoc"},{"issue":"17","key":"5233_CR15","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.2165\/11594630-000000000-00000","volume":"71","author":"JE Chang","year":"2011","unstructured":"Chang JE, Kahl BS (2011) Current status of targeted therapies for mantle cell lymphoma. Drugs 71(17):2307\u20132326. https:\/\/doi.org\/10.2165\/11594630-000000000-00000","journal-title":"Drugs"},{"issue":"1","key":"5233_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3747\/co.22.2393","volume":"22","author":"S Chia","year":"2015","unstructured":"Chia S, Gandhi S, Joy AA, Edwards S, Gorr M, Hopkins S, Kondejewski J, Ayoub JP, Califaretti N, Rayson D, Dent SF (2015) Novel agents and associated toxicities of inhibitors of the pi3k\/Akt\/mtor pathway for the treatment of breast cancer. Curr Oncol 22(1):33\u201348. https:\/\/doi.org\/10.3747\/co.22.2393","journal-title":"Curr Oncol"},{"issue":"144","key":"5233_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003875","volume":"4","author":"JC Choi","year":"2012","unstructured":"Choi JC, Muchir A, Wu W, Iwata S, Homma S, Morrow JP, Worman HJ (2012) Temsirolimus activates autophagy and ameliorates cardiomyopathy caused by lamin A\/C gene mutation. Sci Transl Med 4(144):144ra102. https:\/\/doi.org\/10.1126\/scitranslmed.3003875","journal-title":"Sci Transl Med"},{"issue":"9","key":"5233_CR18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Ju\u00e1rez VM, Hsieh JJ, Basso U, Shah AY, Su\u00e1rez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, \u017bo\u0142nierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384(9):829\u2013841. https:\/\/doi.org\/10.1056\/NEJMoa2026982","journal-title":"N Engl J Med"},{"issue":"12","key":"5233_CR19","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1093\/oncolo\/oyac192","volume":"27","author":"TK Choueiri","year":"2022","unstructured":"Choueiri TK, Porta C, Su\u00e1rez C, Hainsworth J, Voog E, Duran I, Reeves J, Czaykowski P, Castellano D, Chen J, Sedarati F, Powles T (2022) Randomized phase II trial of sapanisertib \u00b1 TAK-117 vs. everolimus in patients with advanced renal cell carcinoma after VEGF-targeted therapy. Oncologist 27(12):1048\u20131057. https:\/\/doi.org\/10.1093\/oncolo\/oyac192","journal-title":"Oncologist"},{"key":"5233_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13235896","author":"A Comandone","year":"2021","unstructured":"Comandone A, Vana F, Comandone T, Tucci M (2021) Antiangiogenic therapy in clear cell renal carcinoma (CCRC): pharmacological basis and clinical results. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13235896","journal-title":"Cancers (Basel)"},{"issue":"10","key":"5233_CR21","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.ejca.2012.03.012","volume":"48","author":"DA Dabydeen","year":"2012","unstructured":"Dabydeen DA, Jagannathan JP, Ramaiya N, Krajewski K, Schutz FA, Cho DC, Pedrosa I, Choueiri TK (2012) Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer 48(10):1519\u20131524. https:\/\/doi.org\/10.1016\/j.ejca.2012.03.012","journal-title":"Eur J Cancer"},{"issue":"3","key":"5233_CR22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/acel.12203","volume":"13","author":"DF Dai","year":"2014","unstructured":"Dai DF, Karunadharma PP, Chiao YA, Basisty N, Crispin D, Hsieh EJ, Chen T, Gu H, Djukovic D, Raftery D, Beyer RP, MacCoss MJ, Rabinovitch PS (2014) Altered proteome turnover and remodeling by short-term caloric restriction or rapamycin rejuvenate the aging heart. Aging Cell 13(3):529\u2013539. https:\/\/doi.org\/10.1111\/acel.12203","journal-title":"Aging Cell"},{"issue":"7","key":"5233_CR23","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ctrv.2012.12.012","volume":"39","author":"R Danesi","year":"2013","unstructured":"Danesi R, Boni JP, Ravaud A (2013) Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications. Cancer Treat Rev 39(7):784\u2013792. https:\/\/doi.org\/10.1016\/j.ctrv.2012.12.012","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"5233_CR24","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.devcel.2009.10.016","volume":"17","author":"WT Dauer","year":"2009","unstructured":"Dauer WT, Worman HJ (2009) The nuclear envelope as a signaling node in development and disease. Dev Cell 17(5):626\u2013638. https:\/\/doi.org\/10.1016\/j.devcel.2009.10.016","journal-title":"Dev Cell"},{"issue":"10","key":"5233_CR25","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.oraloncology.2011.08.009","volume":"47","author":"MA de Oliveira","year":"2011","unstructured":"de Oliveira MA, Martins EMF, Wang Q, Sonis S, Demetri G, George S, Butrynski J, Treister NS (2011) Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol 47(10):998\u20131003. https:\/\/doi.org\/10.1016\/j.oraloncology.2011.08.009","journal-title":"Oral Oncol"},{"issue":"10020","key":"5233_CR26","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/s0140-6736(15)00667-4","volume":"387","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S (2016) Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet 387(10020):770\u2013778. https:\/\/doi.org\/10.1016\/s0140-6736(15)00667-4","journal-title":"Lancet"},{"issue":"3","key":"5233_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2307\/2686093","volume":"53","author":"W DuMouchel","year":"1999","unstructured":"DuMouchel W (1999) Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat 53(3):177\u2013190. https:\/\/doi.org\/10.2307\/2686093","journal-title":"Am Stat"},{"issue":"2","key":"5233_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/jnci\/djr511","volume":"104","author":"T Eisen","year":"2012","unstructured":"Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, Izzedine H, Escudier B (2012) Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 104(2):93\u2013113. https:\/\/doi.org\/10.1093\/jnci\/djr511","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"5233_CR29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10(6):483\u2013486. https:\/\/doi.org\/10.1002\/pds.677","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"5233_CR30","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/07357907.2016.1242009","volume":"34","author":"CA Garcia","year":"2016","unstructured":"Garcia CA, Wu S (2016) Attributable risk of infection to mTOR inhibitors everolimus and temsirolimus in the treatment of cancer. Cancer Invest 34(10):521\u2013530. https:\/\/doi.org\/10.1080\/07357907.2016.1242009","journal-title":"Cancer Invest"},{"issue":"12","key":"5233_CR31","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1517\/13543784.2013.833604","volume":"22","author":"J Hajjar","year":"2013","unstructured":"Hajjar J, Habra MA, Naing A (2013) Metformin: an old drug with new potential. Expert Opin Investig Drugs 22(12):1511\u20131517. https:\/\/doi.org\/10.1517\/13543784.2013.833604","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"5233_CR32","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1093\/annonc\/mdr533","volume":"23","author":"DY Heng","year":"2012","unstructured":"Heng DY, Mackenzie MJ, Vaishampayan UN, Bjarnason GA, Knox JJ, Tan MH, Wood L, Wang Y, Kollmannsberger C, North S, Donskov F, Rini BI, Choueiri TK (2012) Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol 23(6):1549\u20131555. https:\/\/doi.org\/10.1093\/annonc\/mdr533","journal-title":"Ann Oncol"},{"issue":"14","key":"5233_CR33","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.2165\/11204940-000000000-00000","volume":"70","author":"SM Hoy","year":"2010","unstructured":"Hoy SM, McKeage K (2010) Temsirolimus: in relapsed and\/or refractory mantle cell lymphoma. Drugs 70(14):1819\u20131829. https:\/\/doi.org\/10.2165\/11204940-000000000-00000","journal-title":"Drugs"},{"issue":"1","key":"5233_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0754-1","volume":"12","author":"H Hua","year":"2019","unstructured":"Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y (2019) Targeting mTOR for cancer therapy. J Hematol Oncol 12(1):71. https:\/\/doi.org\/10.1186\/s13045-019-0754-1","journal-title":"J Hematol Oncol"},{"key":"5233_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-368","volume":"10","author":"MM Javle","year":"2010","unstructured":"Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA, Abbruzzese JL (2010) Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 10:368. https:\/\/doi.org\/10.1186\/1471-2407-10-368","journal-title":"BMC Cancer"},{"key":"5233_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1520439","volume":"16","author":"T Jiang","year":"2025","unstructured":"Jiang T, Du P, Liu D, Chen H, Ma Y, Hu B, Li J, Jiang H, Li X (2025) Exploring the glucose-lowering and anti-inflammatory immune mechanism of artemether by AMPK\/mTOR pathway and microbiome based on multi-omics. Front Pharmacol 16:1520439. https:\/\/doi.org\/10.3389\/fphar.2025.1520439","journal-title":"Front Pharmacol"},{"issue":"12","key":"5233_CR37","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/annonc\/mdm121","volume":"18","author":"F Joly","year":"2007","unstructured":"Joly F, Vardy J, Pintilie M, Tannock IF (2007) Quality of life and\/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol 18(12):1935\u20131942. https:\/\/doi.org\/10.1093\/annonc\/mdm121","journal-title":"Ann Oncol"},{"issue":"3","key":"5233_CR38","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.trre.2014.03.002","volume":"28","author":"B Kaplan","year":"2014","unstructured":"Kaplan B, Qazi Y, Wellen JR (2014) Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando) 28(3):126\u2013133. https:\/\/doi.org\/10.1016\/j.trre.2014.03.002","journal-title":"Transplant Rev (Orlando)"},{"issue":"4","key":"5233_CR39","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/cpt.2951","volume":"114","author":"C Khouri","year":"2023","unstructured":"Khouri C, Fusaroli M, Salvo F, Raschi E (2023) Interpretation of pharmacovigilance disproportionality analyses. Clin Pharmacol Ther 114(4):745\u2013746. https:\/\/doi.org\/10.1002\/cpt.2951","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"5233_CR40","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/s41374-018-0158-9","volume":"99","author":"N Kokuho","year":"2019","unstructured":"Kokuho N, Terasaki Y, Kunugi S, Saito Y, Urushiyama H, Terasaki M, Hayashi H, Gemma A, Shimizu A (2019) Analyses of alveolar epithelial injury via lipid-related stress in mammalian target of rapamycin inhibitor-induced lung disease. Lab Invest 99(6):853\u2013865. https:\/\/doi.org\/10.1038\/s41374-018-0158-9","journal-title":"Lab Invest"},{"issue":"6","key":"5233_CR41","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1159\/000528985","volume":"69","author":"AH Kuerec","year":"2023","unstructured":"Kuerec AH, Maier AB (2023) Why is rapamycin not a rapalog? Gerontology 69(6):657\u2013659. https:\/\/doi.org\/10.1159\/000528985","journal-title":"Gerontology"},{"issue":"2","key":"5233_CR42","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274\u2013293. https:\/\/doi.org\/10.1016\/j.cell.2012.03.017","journal-title":"Cell"},{"issue":"17","key":"5233_CR43","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/blood.2021015106","volume":"140","author":"S Laukkanen","year":"2022","unstructured":"Laukkanen S, Veloso A, Yan C, Oksa L, Alpert EJ, Do D, Hyv\u00e4rinen N, McCarthy K, Adhikari A, Yang Q, Iyer S, Garcia SP, Pello A, Ruokoranta T, Moisio S, Adhikari S, Yoder JA, Gallagher K, Whelton L, Allen JR, Jin AH, Loontiens S, Hein\u00e4niemi M, Kelliher M, Heckman CA, Lohi O, Langenau DM (2022) Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia. Blood 140(17):1891\u20131906. https:\/\/doi.org\/10.1182\/blood.2021015106","journal-title":"Blood"},{"issue":"4","key":"5233_CR44","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.4143\/crt.2018.671","volume":"51","author":"JB Lee","year":"2019","unstructured":"Lee JB, Park HS, Park S, Lee HJ, Kwon KA, Choi YJ, Kim YJ, Nam CM, Cho NH, Kang B, Chung HC, Rha SY (2019) Temsirolimus in Asian metastatic\/recurrent non-clear cell renal carcinoma. Cancer Res Treat 51(4):1578\u20131588. https:\/\/doi.org\/10.4143\/crt.2018.671","journal-title":"Cancer Res Treat"},{"issue":"4","key":"5233_CR45","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.juro.2009.12.035","volume":"183","author":"BC Leibovich","year":"2010","unstructured":"Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML, Cheville JC (2010) Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 183(4):1309\u20131315. https:\/\/doi.org\/10.1016\/j.juro.2009.12.035","journal-title":"J Urol"},{"key":"5233_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2023.101952","volume":"81","author":"X Li","year":"2023","unstructured":"Li X, Peng Z, An K, Xue M, Wang Z, Xia J, Qi Z, Shu X (2023) Temsirolimus is a promising immunomodulatory agent for enhanced transplantation outcomes. Transpl Immunol 81:101952. https:\/\/doi.org\/10.1016\/j.trim.2023.101952","journal-title":"Transpl Immunol"},{"key":"5233_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00228","volume":"3","author":"JJ Limon","year":"2012","unstructured":"Limon JJ, Fruman DA (2012) Akt and mTOR in B cell activation and differentiation. Front Immunol 3:228. https:\/\/doi.org\/10.3389\/fimmu.2012.00228","journal-title":"Front Immunol"},{"issue":"5","key":"5233_CR48","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","volume":"67","author":"B Ljungberg","year":"2015","unstructured":"Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913\u2013924. https:\/\/doi.org\/10.1016\/j.eururo.2015.01.005","journal-title":"Eur Urol"},{"issue":"5","key":"5233_CR49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2413719122","volume":"122","author":"J Ma","year":"2025","unstructured":"Ma J, Chen Y, Song J, Ruan Q, Li L, Luo L (2025) Establishment and application of a zebrafish model of Werner syndrome identifies sapanisertib as a potential antiaging drug. Proc Natl Acad Sci U S A 122(5):e2413719122. https:\/\/doi.org\/10.1073\/pnas.2413719122","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"5233_CR50","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00228-022-03358-3","volume":"78","author":"MT Madhushika","year":"2022","unstructured":"Madhushika MT, Weerarathna TP, Liyanage P, Jayasinghe SS (2022) Evolution of adverse drug reactions reporting systems: paper based to software based. Eur J Clin Pharmacol 78(9):1385\u20131390. https:\/\/doi.org\/10.1007\/s00228-022-03358-3","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"5233_CR51","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1007\/s00405-015-3694-6","volume":"273","author":"S Mallick","year":"2016","unstructured":"Mallick S, Benson R, Rath GK (2016) Radiation induced oral mucositis: a review of current literature on prevention and management. Eur Arch Otorhinolaryngol 273(9):2285\u20132293. https:\/\/doi.org\/10.1007\/s00405-015-3694-6","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"13","key":"5233_CR52","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1200\/jco.2010.29.2235","volume":"29","author":"JP Maroto","year":"2011","unstructured":"Maroto JP, Hudes G, Dutcher JP, Logan TF, White CS, Krygowski M, Cincotta M, Shapiro M, Duran I, Berkenblit A (2011) Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 29(13):1750\u20131756. https:\/\/doi.org\/10.1200\/jco.2010.29.2235","journal-title":"J Clin Oncol"},{"issue":"7","key":"5233_CR53","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/s1470-2045(17)30355-8","volume":"18","author":"R Mody","year":"2017","unstructured":"Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R (2017) Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol 18(7):946\u2013957. https:\/\/doi.org\/10.1016\/s1470-2045(17)30355-8","journal-title":"Lancet Oncol"},{"issue":"12","key":"5233_CR54","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41568-018-0074-8","volume":"18","author":"D Mossmann","year":"2018","unstructured":"Mossmann D, Park S, Hall MN (2018) mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer 18(12):744\u2013757. https:\/\/doi.org\/10.1038\/s41568-018-0074-8","journal-title":"Nat Rev Cancer"},{"issue":"14","key":"5233_CR55","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Ar\u00e9n Frontera O, Melichar B, Choueiri TK, Plimack ER, Barth\u00e9l\u00e9my P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Escudier B (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"issue":"12","key":"5233_CR56","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr., Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Choueiri TK (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1103\u20131115. https:\/\/doi.org\/10.1056\/NEJMoa1816047","journal-title":"N Engl J Med"},{"issue":"14","key":"5233_CR57","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Gr\u00fcnwald V, Hutson TE, Kopyltsov E, M\u00e9ndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384(14):1289\u20131300. https:\/\/doi.org\/10.1056\/NEJMoa2035716","journal-title":"N Engl J Med"},{"issue":"2","key":"5233_CR58","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1093\/hmg\/ddn343","volume":"18","author":"A Muchir","year":"2009","unstructured":"Muchir A, Shan J, Bonne G, Lehnart SE, Worman HJ (2009) Inhibition of extracellular signal-regulated kinase signaling to prevent cardiomyopathy caused by mutation in the gene encoding A-type lamins. Hum Mol Genet 18(2):241\u2013247. https:\/\/doi.org\/10.1093\/hmg\/ddn343","journal-title":"Hum Mol Genet"},{"issue":"2","key":"5233_CR59","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/cvr\/cvr301","volume":"93","author":"A Muchir","year":"2012","unstructured":"Muchir A, Reilly SA, Wu W, Iwata S, Homma S, Bonne G, Worman HJ (2012) Treatment with selumetinib preserves cardiac function and improves survival in cardiomyopathy caused by mutation in the lamin A\/C gene. Cardiovasc Res 93(2):311\u2013319. https:\/\/doi.org\/10.1093\/cvr\/cvr301","journal-title":"Cardiovasc Res"},{"issue":"2","key":"5233_CR60","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1001\/jamaoncol.2021.4337","volume":"8","author":"V Navani","year":"2022","unstructured":"Navani V, Heng DYC (2022) Treatment selection in first-line metastatic renal cell carcinoma-the contemporary treatment paradigm in the age of combination therapy: a review. JAMA Oncol 8(2):292\u2013299. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4337","journal-title":"JAMA Oncol"},{"issue":"2","key":"5233_CR61","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ctrv.2013.08.004","volume":"40","author":"PF Peddi","year":"2014","unstructured":"Peddi PF, Shatsky RA, Hurvitz SA (2014) Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer. Cancer Treat Rev 40(2):320\u2013326. https:\/\/doi.org\/10.1016\/j.ctrv.2013.08.004","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"5233_CR62","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s00280-014-2600-z","volume":"74","author":"CI Piatek","year":"2014","unstructured":"Piatek CI, Raja GL, Ji L, Gitlitz BJ, Dorff TB, Quinn DI, Hu J, El-Khoueiry AB, Pham HQ, Roman L, Garcia AA (2014) Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer Chemother Pharmacol 74(6):1227\u20131234. https:\/\/doi.org\/10.1007\/s00280-014-2600-z","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"5233_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56914-7","volume":"16","author":"M Piffoux","year":"2025","unstructured":"Piffoux M, Leary A, Follana P, Abdeddaim C, Joly F, Bin S, Bonjour M, Boulai A, Callens C, Villeneuve L, Alexandre M, Schwiertz V, Freyer G, Rodrigues M, You B (2025) Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced\/metastatic endometrial cancer: the ENDOLA phase I\/II trial. Nat Commun 16(1):1821. https:\/\/doi.org\/10.1038\/s41467-025-56914-7","journal-title":"Nat Commun"},{"issue":"5","key":"5233_CR64","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1158\/1078-0432.Ccr-07-4719","volume":"14","author":"BI Rini","year":"2008","unstructured":"Rini BI (2008) Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res 14(5):1286\u20131290. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-4719","journal-title":"Clin Cancer Res"},{"issue":"9669","key":"5233_CR65","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/s0140-6736(09)60229-4","volume":"373","author":"BI Rini","year":"2009","unstructured":"Rini BI, Campbell SC, Escudier B (2009) Renal cell carcinoma. Lancet 373(9669):1119\u20131132. https:\/\/doi.org\/10.1016\/s0140-6736(09)60229-4","journal-title":"Lancet"},{"issue":"12","key":"5233_CR66","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Souli\u00e8res D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Powles T (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa1816714","journal-title":"N Engl J Med"},{"issue":"20","key":"5233_CR67","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.2217\/fon-2021-0069","volume":"17","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Mollica V, Dall\u2019Olio FG, Ricci AD, Maggio I, Marchetti A, Rosellini M, Santoni M, Ardizzoni A, Massari F (2021) Quality of life assessment in renal cell carcinoma\u00a0phase II and III clinical trials published between 2010 and 2020: a systematic review. Future Oncol 17(20):2671\u20132681. https:\/\/doi.org\/10.2217\/fon-2021-0069","journal-title":"Future Oncol"},{"issue":"8","key":"5233_CR68","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13(8):519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"5233_CR69","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/s1470-2045(17)30109-2","volume":"18","author":"HS Rugo","year":"2017","unstructured":"Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia C, Mayer IA, Meiller TF, Chambers MS, Sweetman RW, Sabo JR, Litton JK (2017) Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol 18(5):654\u2013662. https:\/\/doi.org\/10.1016\/s1470-2045(17)30109-2","journal-title":"Lancet Oncol"},{"key":"5233_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16213689","author":"TK Sahin","year":"2024","unstructured":"Sahin TK, Ayasun R, Rizzo A, Guven DC (2024) Prognostic value of neutrophil-to-eosinophil ratio (NER) in cancer: a systematic review and meta-analysis. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16213689","journal-title":"Cancers (Basel)"},{"issue":"6","key":"5233_CR71","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.euf.2022.02.004","volume":"8","author":"M Santoni","year":"2022","unstructured":"Santoni M, Massari F, Bracarda S, Grande E, Matrana MR, Rizzo M, De Giorgi U, Basso U, Aurilio G, Incorvaia L, Martignetti A, Molina-Cerrillo J, Mollica V, Rizzo A, Battelli N (2022) Cabozantinib in patients with advanced renal cell carcinoma primary refractory to first-line immunocombinations or tyrosine kinase inhibitors. Eur Urol Focus 8(6):1696\u20131702. https:\/\/doi.org\/10.1016\/j.euf.2022.02.004","journal-title":"Eur Urol Focus"},{"issue":"1","key":"5233_CR72","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.euo.2023.07.003","volume":"7","author":"M Santoni","year":"2024","unstructured":"Santoni M, Buti S, Myint ZW, Maruzzo M, Iacovelli R, Pichler M, Kopecky J, Kucharz J, Rizzo M, Galli L, B\u00fcttner T, De Giorgi U, Kanesvaran R, Fiala O, Grande E, Zucali PA, Kopp RM, Fornarini G, Bourlon MT, Porta C (2024) Real-world outcome of patients with advanced renal cell carcinoma and intermediate- or poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria treated by immune-oncology combinations: differential effectiveness by risk group? Eur Urol Oncol 7(1):102\u2013111. https:\/\/doi.org\/10.1016\/j.euo.2023.07.003","journal-title":"Eur Urol Oncol"},{"key":"5233_CR73","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/978-3-642-54490-3_24","volume":"201","author":"M Schulze","year":"2014","unstructured":"Schulze M, Stock C, Zaccagnini M, Teber D, Rassweiler JJ (2014) Temsirolimus. Recent Results Cancer Res 201:393\u2013403. https:\/\/doi.org\/10.1007\/978-3-642-54490-3_24","journal-title":"Recent Results Cancer Res"},{"key":"5233_CR74","doi-asserted-by":"publisher","DOI":"10.1172\/jci160766","author":"G Shi","year":"2022","unstructured":"Shi G, Chiramel AI, Li T, Lai KK, Kenney AD, Zani A, Eddy AC, Majdoul S, Zhang L, Dempsey T, Beare PA, Kar S, Yewdell JW, Best SM, Yount JS, Compton AA (2022) Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2. J Clin Invest. https:\/\/doi.org\/10.1172\/jci160766","journal-title":"J Clin Invest"},{"issue":"1","key":"5233_CR75","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.trim.2014.05.002","volume":"31","author":"F Shihab","year":"2014","unstructured":"Shihab F, Christians U, Smith L, Wellen JR, Kaplan B (2014) Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. Transpl Immunol 31(1):22\u201332. https:\/\/doi.org\/10.1016\/j.trim.2014.05.002","journal-title":"Transpl Immunol"},{"issue":"1","key":"5233_CR76","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"5233_CR77","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2165\/11585040-000000000-00000","volume":"34","author":"S Sofroniadou","year":"2011","unstructured":"Sofroniadou S, Goldsmith D (2011) Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects. Drug Saf 34(2):97\u2013115. https:\/\/doi.org\/10.2165\/11585040-000000000-00000","journal-title":"Drug Saf"},{"issue":"8","key":"5233_CR78","doi-asserted-by":"publisher","first-page":"11087","DOI":"10.1096\/fj.202001062R","volume":"34","author":"E Song","year":"2020","unstructured":"Song E, Wang RS, Leopold JA, Loscalzo J (2020) Network determinants of cardiovascular calcification and repositioned drug treatments. FASEB J 34(8):11087\u201311100. https:\/\/doi.org\/10.1096\/fj.202001062R","journal-title":"FASEB J"},{"key":"5233_CR79","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/978-3-642-01222-8_13","volume":"184","author":"C Stock","year":"2010","unstructured":"Stock C, Zaccagnini M, Schulze M, Teber D, Rassweiler JJ (2010) Temsirolimus. Recent Results Cancer Res 184:189\u2013197. https:\/\/doi.org\/10.1007\/978-3-642-01222-8_13","journal-title":"Recent Results Cancer Res"},{"issue":"2","key":"5233_CR80","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1158\/2767-9764.Crc-22-0260","volume":"4","author":"V Subbiah","year":"2024","unstructured":"Subbiah V, Coleman N, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EEI, Fu S, Hong DS, Zhang S, Sun M, Jiang Y, Roszik J, Song J, Yuan Y, Meric-Bernstam F, Naing A (2024) Phase I study of mTORC1\/2 inhibitor sapanisertib (CB-228\/TAK-228) in combination with metformin in patients with mTOR\/AKT\/PI3K pathway alterations and advanced solid malignancies. Cancer Res Commun 4(2):378\u2013387. https:\/\/doi.org\/10.1158\/2767-9764.Crc-22-0260","journal-title":"Cancer Res Commun"},{"key":"5233_CR81","unstructured":"Temsirolimus (2012)\u00a0LiverTox: clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Instituteof Diabetes and Digestive and Kidney Diseases"},{"issue":"2S Suppl 1","key":"5233_CR82","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1097\/tp.0000000000001722","volume":"102","author":"B Verg\u00e8s","year":"2018","unstructured":"Verg\u00e8s B (2018) mTOR and cardiovascular diseases: diabetes mellitus. Transplantation 102(2S Suppl 1):S47-s49. https:\/\/doi.org\/10.1097\/tp.0000000000001722","journal-title":"Transplantation"},{"issue":"2","key":"5233_CR83","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.diabres.2015.09.014","volume":"110","author":"B Verg\u00e8s","year":"2015","unstructured":"Verg\u00e8s B, Cariou B (2015) mTOR inhibitors and diabetes. Diabetes Res Clin Pract 110(2):101\u2013108. https:\/\/doi.org\/10.1016\/j.diabres.2015.09.014","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"5233_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02385-0","volume":"11","author":"F Wang","year":"2025","unstructured":"Wang F, Li L, Sun X, Cai X, Wang J, Luo H, Wang Y, Ni D, Wang D (2025) The feedback loop between miR-222-3p and ZEB1 harnesses metastasis in renal cell carcinoma. Cell Death Discov 11(1):97. https:\/\/doi.org\/10.1038\/s41420-025-02385-0","journal-title":"Cell Death Discov"},{"issue":"12","key":"5233_CR85","doi-asserted-by":"publisher","first-page":"L1117","DOI":"10.1152\/ajplung.00251.2013","volume":"306","author":"S Washino","year":"2014","unstructured":"Washino S, Ando H, Ushijima K, Hosohata K, Kumazaki M, Mato N, Sugiyama Y, Kobayashi Y, Fujimura A, Morita T (2014) Temsirolimus induces surfactant lipid accumulation and lung inflammation in mice. Am J Physiol Lung Cell Mol Physiol 306(12):L1117-1128. https:\/\/doi.org\/10.1152\/ajplung.00251.2013","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1","key":"5233_CR86","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1161\/circulationaha.110.970673","volume":"123","author":"W Wu","year":"2011","unstructured":"Wu W, Muchir A, Shan J, Bonne G, Worman HJ (2011) Mitogen-activated protein kinase inhibitors improve heart function and prevent fibrosis in cardiomyopathy caused by mutation in lamin A\/C gene. Circulation 123(1):53\u201361. https:\/\/doi.org\/10.1161\/circulationaha.110.970673","journal-title":"Circulation"},{"issue":"1","key":"5233_CR87","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1185\/03007995.2013.844116","volume":"30","author":"J Xu","year":"2014","unstructured":"Xu J, Tian D (2014) Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis. Curr Med Res Opin 30(1):67\u201374. https:\/\/doi.org\/10.1185\/03007995.2013.844116","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"5233_CR88","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.smim.2012.12.005","volume":"24","author":"X Xu","year":"2012","unstructured":"Xu X, Ye L, Araki K, Ahmed R (2012) mTOR, linking metabolism and immunity. Semin Immunol 24(6):429\u2013435. https:\/\/doi.org\/10.1016\/j.smim.2012.12.005","journal-title":"Semin Immunol"},{"key":"5233_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1452300","volume":"15","author":"W Ye","year":"2024","unstructured":"Ye W, Ding Y, Li M, Tian Z, Wang S, Liu Z (2024) Safety assessment of sulfasalazine: a pharmacovigilance study based on FAERS database. Front Pharmacol 15:1452300. https:\/\/doi.org\/10.3389\/fphar.2024.1452300","journal-title":"Front Pharmacol"},{"issue":"1","key":"5233_CR90","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10549-010-0763-9","volume":"123","author":"M Zakikhani","year":"2010","unstructured":"Zakikhani M, Blouin MJ, Piura E, Pollak MN (2010) Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 123(1):271\u2013279. https:\/\/doi.org\/10.1007\/s10549-010-0763-9","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"5233_CR91","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.4049\/jimmunol.1201767","volume":"191","author":"S Zhang","year":"2013","unstructured":"Zhang S, Pruitt M, Tran D, Du Bois W, Zhang K, Patel R, Hoover S, Simpson RM, Simmons J, Gary J, Snapper CM, Casellas R, Mock BA (2013) B cell-specific deficiencies in mTOR limit humoral immune responses. J Immunol 191(4):1692\u20131703. https:\/\/doi.org\/10.4049\/jimmunol.1201767","journal-title":"J Immunol"},{"key":"5233_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1333662","volume":"15","author":"B Zhao","year":"2024","unstructured":"Zhao B, Fu Y, Cui S, Chen X, Liu S, Luo L (2024) A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system. Front Pharmacol 15:1333662. https:\/\/doi.org\/10.3389\/fphar.2024.1333662","journal-title":"Front Pharmacol"},{"issue":"3","key":"5233_CR93","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/s1875-5364(13)60035-7","volume":"11","author":"RC Zink","year":"2013","unstructured":"Zink RC, Huang Q, Zhang LY, Bao WJ (2013) Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance. Chin J Nat Med 11(3):314\u2013320. https:\/\/doi.org\/10.1016\/s1875-5364(13)60035-7","journal-title":"Chin J Nat Med"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05233-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05233-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05233-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:44:11Z","timestamp":1783907051000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05233-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":93,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5233"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05233-9","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}